ASPEAspen Neuroscience

US ExchangeHealth Care2026-10-30

Clinical-stage regenerative medicine company developing autologous iPSC-derived therapies for neurodegenerative diseases like Parkinson's.

$15IPO price

$141MRaised

$14.89Day-1 close

-0.73%Day-1 return

Clinical-stage regenerative medicine company developing autologous iPSC-derived therapies for neurodegenerative diseases like Parkinson's.

Company description (source: StockAnalysis)

Aspen Neuroscience is a leading, clinical-stage regenerative medicine biotechnology company focused on developing autologous induced-pluripotent stem cell (iPSC)-derived therapies to address neurodegenerative diseases with high unmet medical need. Our lead product candidate, sasineprocel, is an investigational single-dose, autologous iPSC-based cell therapy being evaluated for the treatment of Parkinson’s disease (PD). We believe sasineprocel has the potential to be disease-modifying by primarily replacing a patient’s lost dopaminergic (DA) neu...

生物医药细胞治疗神经科学

51CFO read: Requires CFO expertise in FDA clinical-stage financial compliance, CMC cost modeling for cell therapy, and IPO fundraising timing for early

Management details per the SEC prospectus.

Company profile SEC prospectus

Does your company need this kind of CFO?

51CFO is an investment banking team focused on the US market: US IPOs, reverse mergers, shell deals, SPAC and De-SPAC, SEC filings and post-listing follow-ons, run by one team from structure to opening bell. Free 30-minute listing-route diagnosis, answered within 24 hours.

Talk to us